The experimental cancer drug Blenrep, in combination with other treatments, reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse, compared with an existing treatment.
An interim analysis of data from a trial dubbed “DREAMM-7” showed the drug – in combination with bortezomib plus the steroid dexamethasone – showed statistically significant overall survival results compared with a standard of care daratumumab combination as a second line or later treatment of relapsed or refractory multiple myeloma, GSK, said.
Reuters reports that multiple myeloma is the third most common type of blood cancer and is generally considered treatable but not curable.
The data projects that on average, patients on the Blenrep combination will survive nearly three years longer, GSK said.
“This represents an important advancement that could redefine the treatment of relapsed or refractory multiple myeloma,” GSK's head of oncology Hesham Abdullah said.
GSK is gearing up for five major new drug launches in 2025, including Blenrep.
Blenrep had seen several setbacks over the past couple of years after it was pulled from the US markets in 2022 when it failed a late-stage study designed to show that it was better than an existing treatment.
However, positive results from the DREAMM-7 and DREAMM-8 trials over the past year could mean a comeback for the drug.
GSK has recently refiled a licence application for Blenrep in combinations with bortezomib plus dexamethasone and pomalidomide plus dexamethasone.
The US Food and Drug Administration (FDA) is expected to make a decision in July 2025.
Earlier on Monday, GSK said the Blenrep combination was accepted for priority review in China in relapsed or refractory multiple myeloma.
See more from MedicalBrief archives:
EU watchdog blocks GSK blood cancer drug approval
Israeli treatment has 90% success rate for multiple myeloma